Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
Authors
Kimutai, RMusa, AM
Njoroge, S
Omollo, R
Alves, F
Hailu, A
Khalil, EAG
Diro, E
Soipei, P
Musa, B
Salman, K
Ritmeijer, K
Chappuis, F
Rashid, J
Mohammed, R
Jameneh, A
Makonnen, E
Olobo, J
Okello, L
Sagaki, P
Strub, N
Ellis, S
Alvar, J
Balasegaram, M
Alirol, E
Wasunna, M
Issue Date
2017-01-09Submitted date
2017-01-18
Metadata
Show full item recordJournal
Clinical Drug InvestigationAbstract
In 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscular (IM) sodium stibogluconate (SSG) and IM paromomycin (PM) was an improvement over SSG monotherapy, the previous first-line VL treatment in the region. To monitor the new treatment's safety and effectiveness in routine clinical practice a pharmacovigilance (PV) programme was developed.Publisher
Springer LinkPubMed ID
28066878Language
enISSN
1179-1918ae974a485f413a2113503eed53cd6c53
10.1007/s40261-016-0481-0
Scopus Count
Collections
Related articles
- Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
- Authors: Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M
- Issue date: 2012
- Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
- Authors: Atia AM, Mumina A, Tayler-Smith K, Boulle P, Alcoba G, Elhag MS, Alnour M, Shah S, Chappuis F, van Griensven J, Zachariah R
- Issue date: 2015 Dec
- Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
- Authors: Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN
- Issue date: 2007 Jul
- Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.
- Authors: Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J, Leishmaniasis East Africa Platform (LEAP) group.
- Issue date: 2010 Oct 26
- Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
- Authors: Hossain MS, Kumar A, Hossain AFMA, Mahshin M, Sharma A, Hossain MA, Sharma V, Haque R, Shamsuzzaman AKM, Maruf S, Ghosh P, Ahuja V, Mondal D
- Issue date: 2018 Aug 13